Atai Life Sciences N.V. (ATAI)
$
2.75
-0.02 (-0.73%)
Key metrics
Financial statements
Free cash flow per share
-0.4413
Market cap
552.1 Million
Price to sales ratio
296.3343
Debt to equity
0.0937
Current ratio
4.0693
Income quality
0.5187
Average inventory
0
ROE
-1.0240
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company focused on developing therapeutic candidates aimed at addressing various mental health disorders. The operating expenses amount to $102,999,000.00 encompassing various operational costs incurred. The total costs and expenses for the company are $102,999,000.00 reflecting its overall spending. Among its therapeutic candidates are PCN-101, a subcutaneous formulation of R-ketamine for treating treatment-resistant depression (TRD); RL-007, a modulator targeting cholinergic, glutamatergic, and GABA-B receptors to address cognitive impairment related to schizophrenia; and DMX-1002, an oral formulation of ibogaine targeting opioid use disorder (OUD). Other notable candidates include GRX-917, aimed at treating generalized anxiety disorder, and NN-101, a novel intranasal formulation of N-acetylcysteine for mild traumatic brain injuries. The net income ratio is -484.64 reflecting the company's profitability margin, while the earnings per share (EPS) is reported at -$0.93 indicating profitability on a per-share basis. Additionally, the weighted average number of diluted shares outstanding is 160,159,983.00 reflecting potential dilution effects. Atai Life Sciences N.V., formerly known as Adripa Holding B.V., was founded in 2018 and is headquartered in Berlin, Germany. The stock is affordable at $2.75 making it suitable for budget-conscious investors. With a market capitalization of $552,070,750.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. The stock also has a high average trading volume of 3,296,596.00 indicating strong liquidity, and it belongs to the Healthcare sector, driving innovation and growth. These characteristics underscore the company's role in reshaping the therapeutic landscape for mental health disorders while offering potential investment opportunities.
Investing in Atai Life Sciences N.V. (ATAI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Atai Life Sciences N.V. stock to fluctuate between $1.03 (low) and $2.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-07, Atai Life Sciences N.V.'s market cap is $552,070,750, based on 200,753,000 outstanding shares.
Compared to WAL-MART STORES INC, Atai Life Sciences N.V. has a Lower Market-Cap, indicating a difference in performance.
Atai Life Sciences N.V. pays dividends. The current dividend yield is 327.87%, with a payout of $6 per share.
To buy Atai Life Sciences N.V. (ATAI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATAI. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Revenue: $308,000 | EPS: -$0.93 | Growth: 272%.
Visit https://www.atai.life/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $22.91 (2021-06-18) | All-time low: $1.03 (2023-12-01).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing treatment paradigms, potentially rivaling J&J's Spravato if regulatory hurdles are cleared. Regulatory approval remains uncertain due to controlled substance scheduling, but Atai's differentiated pipeline and patent position offer significant long-term upside.
proactiveinvestors.com
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant depression, and a private placement for gross proceeds of $50 million. The clincial study, in partnership with Beckley Psytech, is evaluating BPL-003, a formulation of the psychedelic compound mebufotenin, also known as DMT, that is administered using a nasal spray.
benzinga.com
Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD).
globenewswire.com
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1
globenewswire.com
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints. At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg comparator group (p = 0.0038). For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p=0.0025 for change vs. 0.3 mg control). Notably, both the 8mg and 12mg doses of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with effects generally maintained out to Week 8.
zacks.com
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
proactiveinvestors.com
The psychedelics sector is experiencing a resurgence of optimism in 2025 driven by a more favorable federal government under President Donald Trump's administration, shifting state-level policies, and encouraging clinical trial results supporting the efficacy of psychedelic therapies. A major setback for the sector was the Food and Drug Administration rejecting Lykos Therapeutics' MDMA-assisted therapy for post-traumatic stress disorder in August last year.
globenewswire.com
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Atai Life Sciences N.V. (NASDAQ: ATAI ) related to the acquisition of Beckley Psytech Limited. Is it a fair deal?
zacks.com
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
zacks.com
Here is how atai Life Sciences N.V. (ATAI) and Novartis (NVS) have performed compared to their sector so far this year.
See all news